Loading...
XKRX215600
Market cap228mUSD
Dec 27, Last price  
2,450.00KRW
1D
-2.20%
1Q
-13.43%
Jan 2017
-73.30%
IPO
-70.02%
Name

SillaJen Inc

Chart & Performance

D1W1MN
XKRX:215600 chart
P/E
—
P/S
85.38
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
8.22%
Rev. gr., 5y
-12.57%
Revenues
3.94b
-21.42%
2,085,870,7301,809,856,6515,292,317,5316,864,849,4677,712,024,8119,068,581,3131,669,716,316254,362,8165,013,362,9913,939,558,690
Net income
-20.37b
L-17.18%
-2,477,889,950-55,853,786,856-74,037,961,067-57,020,831,505-56,236,181,150-113,199,973,347-47,824,888,873-15,305,323,904-24,593,128,293-20,369,238,698
CFO
-17.02b
L-23.14%
-17,126,243,559-22,387,351,251-45,613,818,660-40,074,633,685-49,315,767,188-56,855,416,000-42,927,145,098-9,706,479,197-22,139,955,054-17,017,385,200
Earnings
Mar 19, 2025

Profile

SillaJen, Inc. engages in the development and commercialization of oncolytic immunotherapy products. The company's lead product is Pexa-Vec, which is in Phase II clinical trial for the treatment of advanced liver cancer. It also develops JX-970 for the treatment of tumor tissues; and JX-900 is a series of modified vaccinia vaccine. The company was founded in 2006 and is headquartered in Seoul, South Korea.
URL
http://www.sillajen.com/
IPO date
Dec 06, 2016
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
3,939,559
-21.42%
5,013,363
1,870.95%
254,363
-84.77%
Cost of revenue
15,588,960
49,241,051
28,314,420
Unusual Expense (Income)
NOPBT
(11,649,401)
(44,227,688)
(28,060,057)
NOPBT Margin
Operating Taxes
187,998
691,673
(6,819,166)
Tax Rate
NOPAT
(11,837,399)
(44,919,360)
(21,240,891)
Net income
(20,369,239)
-17.18%
(24,593,128)
60.68%
(15,305,324)
-68.00%
Dividends
Dividend yield
Proceeds from repurchase of equity
97,725,339
BB yield
Debt
Debt current
720,388
8,262,669
10,607,546
Long-term debt
10,536,998
6,953,010
6,164,777
Deferred revenue
Other long-term liabilities
182,091
263,680
474,861
Net debt
(39,963,149)
(51,035,723)
(101,322,525)
Cash flow
Cash from operating activities
(17,017,385)
(22,139,955)
(9,706,479)
CAPEX
(351,435)
(19,454,578)
(70,756)
Cash from investing activities
36,326,061
(10,217,555)
8,399,384
Cash from financing activities
(8,349,606)
(4,078,564)
96,834,846
FCF
(6,344,645)
(50,910,328)
(20,720,832)
Balance
Cash
49,296,989
62,456,551
108,263,382
Long term investments
1,923,548
3,794,850
9,831,465
Excess cash
51,023,558
66,000,733
118,082,129
Stockholders' equity
(376,356,814)
(347,192,469)
(316,610,523)
Invested Capital
443,549,487
441,481,608
441,463,510
ROIC
ROCE
EV
Common stock shares outstanding
113,178
111,058
91,216
Price
6,030.00
-13.49%
6,970.00
 
Market cap
682,463,298
-11.83%
774,072,531
 
EV
642,500,148
723,036,809
EBITDA
(10,503,626)
(43,029,480)
(26,920,445)
EV/EBITDA
Interest
1,683,063
2,079,110
2,809,797
Interest/NOPBT